pavtide accuhaler 250/50 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack
glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation) - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.
airzate accuhaler 500/50 fluticasone propionate 500 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack
glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. airzate is not indicated for the initiation of bronchodilator therapy in copd.
airzate accuhaler 100/50 fluticasone propionate 100 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack
glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. airzate is not indicated for the initiation of bronchodilator therapy in copd.
advair diskus fluticasone propionate and salmeterol powder
lake erie medical & surgical supply dba quality care products llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug
advair diskus- fluticasone propionate and salmeterol powder
remedyrepack inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. advair diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta 2 -adrenergic agonist (laba). important limitation of use advair diskus is not indicated for the relief of acute bronchospasm. advair diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. advair diskus 250/50 is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. advair diskus 250/50 twice daily is the only approved dosage for the treatment of copd because an efficacy advantage of the higher strength advair diskus 500/50 over advair diskus 250/50 has not been demonstrated. impo
advair diskus- fluticasone propionate and salmeterol powder
glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. advair diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use advair diskus is not indicated for the relief of acute bronchospasm. advair diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. advair diskus 250/50 is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. advair diskus 250/50 twice daily is the only approved dosage for the treatment of copd because an efficacy advantage of the higher strength advair diskus 500/50 over advair diskus 250/50 has not been demonstrated. important limitatio
salmeterol 25micrograms/dose inhaler
waymade healthcare plc - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose
salmeterol 25micrograms/dose inhaler
dowelhurst ltd - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose
salmeterol 50microgram diskhaler
dowelhurst ltd - salmeterol xinafoate - inhalation powder - 50microgram
salmeterol 25micrograms/dose inhaler cfc free
a a h pharmaceuticals ltd - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose